Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Cristoforo Incorvaia, Marina Mauro, Marina Russello, Chiara Formigoni, Gian Galeazzo Riario-Sforza & Erminia Ridolo. (2014) Omalizumab, an anti-immunoglobulin E antibody: state of the art. Drug Design, Development and Therapy 8, pages 197-207.
Read now
Read now
K Suresh Babu, Riccardo Polosa & Jaymin B Morjaria. (2013) Anti-IgE – emerging opportunities for Omalizumab. Expert Opinion on Biological Therapy 13:5, pages 765-777.
Read now
Read now
Adrian Gillissen. (2007) American Thoracic Society Annual International Congress. Expert Opinion on Pharmacotherapy 8:16, pages 2885-2891.
Read now
Read now
Andrea Leonardi. (2007) New drug treatments for ocular allergies. Expert Review of Ophthalmology 2:3, pages 397-408.
Read now
Read now
Articles from other publishers (23)
Serge Doan, Nikolaos G. Papadopoulos, Jason K. Lee, Salvatore Leonardi, Sara Manti, Susanne Lau, Carmen Rondon, Vibha Sharma, Uwe Pleyer, Xavier Jaumont & Slawomir B. Lazarewicz. (2023) Vernal keratoconjunctivitis: Current immunological and clinical evidence and the potential role of omalizumab. World Allergy Organization Journal 16:6, pages 100788.
Crossref
Crossref
Ken Fukuda, Tatsuma Kishimoto, Tamaki Sumi, Kenji Yamashiro & Nobuyuki Ebihara. (2023) Biologics for allergy: therapeutic potential for ocular allergic diseases and adverse effects on the eye. Allergology International 72:2, pages 234-244.
Crossref
Crossref
Siri Rossberg, Uwe Pleyer & Susanne Lau. (2020) Omalizumab in three children with severe vernal keratoconjunctivitis. Allergo Journal International 29:6, pages 181-186.
Crossref
Crossref
Siri Rossberg, Uwe Pleyer & Susanne Lau. (2020) Omalizumab in three children with severe vernal keratoconjunctivitis. Allergo Journal 29:6, pages 28-35.
Crossref
Crossref
Alessia Gatta, Loredana Della Valle, Anila Farinelli, Gilda Scarano, Arianna Lumaca, Enrico Cavallucci, Mario Di Gioacchino & Roberto Paganelli. (2020) Vernal Keratoconjunctivitis: A Case of Anti-IgE Treatment with Short-Lasting Remission. Case Reports in Ophthalmology 11:2, pages 268-275.
Crossref
Crossref
Stephen D. Anesi, Peter Y. Chang & C. Stephen Foster. 2020. Foundations of Corneal Disease. Foundations of Corneal Disease
121
138
.
Nir Erdinest, Hadas Ben-Eli & Abraham Solomon. (2019) Topical tacrolimus for allergic eye diseases. Current Opinion in Allergy & Clinical Immunology 19:5, pages 535-543.
Crossref
Crossref
Andrea Leonardi, Diana Silva, Daniel Perez Formigo, Banu Bozkurt, Vibha Sharma, Pia Allegri, Carmen Rondon, Virginia Calder, Dermot Ryan, Marek L. Kowalski, Luis Delgado, Serge Doan & Jean L. Fauquert. (2019) Management of ocular allergy. Allergy 74:9, pages 1611-1630.
Crossref
Crossref
Rachel S. Simpson & Jason K. Lee. (2019) Omalizumab as single-dose therapy for vernal keratoconjunctivitis. Annals of Allergy, Asthma & Immunology 122:1, pages 119-120.
Crossref
Crossref
Serge Doan, Flore Amat, Eric Gabison, Sarah Saf, Isabelle Cochereau & Jocelyne Just. (2016) Omalizumab in Severe Refractory Vernal Keratoconjunctivitis in Children: Case Series and Review of the Literature. Ophthalmology and Therapy 6:1, pages 195-206.
Crossref
Crossref
Brett P. Bielory, Steven P. Shah, Terrence P. O’Brien, Victor L. Perez & Leonard Bielory. (2016) Emerging therapeutics for ocular surface disease. Current Opinion in Allergy & Clinical Immunology 16:5, pages 477-486.
Crossref
Crossref
NikhilS Gokhale. (2016) Systematic approach to managing vernal keratoconjunctivitis in clinical practice: Severity grading system and a treatment algorithm. Indian Journal of Ophthalmology 64:2, pages 145.
Crossref
Crossref
Arnau Navinés-Ferrer, Eva Serrano-Candelas, Gustavo-J Molina-Molina & Margarita Martín. (2016) IgE-Related Chronic Diseases and Anti-IgE-Based Treatments. Journal of Immunology Research 2016, pages 1-12.
Crossref
Crossref
Ibon Eguíluz-Gracia, Teresa Robledo-Echarren, Ricardo Suárez-Fernández, Montserrat Fernández-Rivas & Silvia Sánchez-Ramón. (2015) Omalizumab for the treatment of atopic dermatitis. Clinical Investigation 5:2, pages 121-136.
Crossref
Crossref
Timothy A. de Klerk, Vibha Sharma, Peter D. Arkwright & Susmito Biswas. (2013) Severe vernal keratoconjunctivitis successfully treated with subcutaneous omalizumab. Journal of American Association for Pediatric Ophthalmology and Strabismus 17:3, pages 305-306.
Crossref
Crossref
Laura Motterle. 2012. Ocular Surface. Ocular Surface
182
190
.
J. Sanchez, R. Ramirez, S. Diez, S. Sus, A. Echenique, M. Olivares & R. Cardona. (2012) Omalizumab beyond asthma. Allergologia et Immunopathologia 40:5, pages 306-315.
Crossref
Crossref
J. Sánchez & R. Cardona. (2012) Omalizumab. An option in vernal keratoconjunctivitis?. Allergologia et Immunopathologia 40:5, pages 319-320.
Crossref
Crossref
Brett Bielory & Leonard Bielory. (2010) Atopic Dermatitis and Keratoconjunctivitis. Immunology and Allergy Clinics of North America 30:3, pages 323-336.
Crossref
Crossref
Inez B.Y. Wong & Ken K. Nischal. (2010) Managing a child with an external ocular disease. Journal of American Association for Pediatric Ophthalmology and Strabismus 14:1, pages 68-77.
Crossref
Crossref
M. G. Danilets, N. V. Belska, Y. P. Bel’sky, E. G. Uchasova, E. S. Trophimova, A. A. Ligatcheva, A. M. Guriev, M. V. Belousov, R. R. Ahmedganov, M. S. Usubov & V. I. Agaphonov. (2009) Effects of Plant Water-Soluble Polysaccharides on the Production of Immunoglobulins E and G1 by Lymphocytes of Mice Sensitized with Ovalbumin. Bulletin of Experimental Biology and Medicine 146:5, pages 585-587.
Crossref
Crossref
Margarita Calonge & José M Herreras. (2007) Clinical grading of atopic keratoconjunctivitis. Current Opinion in Allergy & Clinical Immunology 7:5, pages 442-445.
Crossref
Crossref
Z. Peng, Q. Liu, Q. Wang, E. Rector, Y. Ma & R. Warrington. (2007) Novel IgE peptide-based vaccine prevents the increase of IgE and down-regulates elevated IgE in rodents. Clinical & Experimental Allergy 37:7, pages 1040-1048.
Crossref
Crossref